Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

Todd Neale

March 22, 2022

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

L.A. McKeown

February 22, 2022

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

Shelley Wood

August 04, 2021

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

L.A. McKeown

March 17, 2021

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Todd Neale

May 04, 2018

News Daily News

‘Practical Guide’ for NOACs Gets an Update

Todd Neale

March 20, 2018

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

Advertisement

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

Fewer Diabetic Complications Seen When NOACs Given for AF

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

‘Practical Guide’ for NOACs Gets an Update

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content